Indivisual Technology of Hanmi ‘Lapscovery’ New Drug Coming Soon
Hanmi has turned on its green light for commercialization of bio new drug that utilized lapscovery platform technology.
A neutropenia treatment, ‘LAPS-GCSF’, successfully finished the phase II clinical study and is going to start the phase III soon.
Hanmi is in the process of developing a new d...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
